BIOMARCADORES PARA DIAGNÓSTICO DE ENFERMEDAD INFLAMATORIA INTESTINAL

VolverVolver

Resultados 45 resultados LastUpdate Última actualización 15/07/2019 [18:47:00] pdf PDF

Solicitudes publicadas en los últimos 150 días / Applications published in the last 150 days

Página1 de 2 nextPage   por página


METHODS OF USING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE TL1A GENE TO PREDICT OR DIAGNOSE INFLAMMATORY BOWEL DISEASE

NºPublicación: US2019211400A1 11/07/2019

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

US_2017166967_A1

Resumen de: US2019211400A1

This invention provides methods of diagnosing or predicting susceptibility to Inflammatory Bowel Disease by determining the presence or absence of genetic variants in the TL1A gene. In one embodiment, a method of the invention is practiced by determining the presence or absence of TL1A production following Fc-gamma-R activation. In another embodiment, the invention provides methods of treatment of inflammatory bowel disease by inhibition of TL1A.

traducir

NANOVESICLE DERIVED FROM PROTEUS GENUS BACTERIA, AND USE THEREOF

NºPublicación: US2019209624A1 11/07/2019

Solicitante:

MD HEALTHCARE INC [KR]

KR_20190003359_A

Resumen de: US2019209624A1

Provided are vesicles derived from bacteria belonging to the genus Proteus and a use thereof. The inventors of the present invention experimentally confirmed that the vesicles was significantly reduced in samples of patients with cancers, allergic-respiratory diseases, cardiovascular diseases, metabolic diseases, or neuropsychiatric diseases, as compared to that of normal people, and the vesicles inhibited the secretion of inflammatory mediators due to pathogenic vesicles and also exhibited anticancer efficacy. Therefore, it is anticipated that the vesicles derived from bacteria belonging to the genus Proteus, according to the present invention, may be usefully used for the development of a method of diagnosing cancer, cardiovascular diseases, metabolic diseases, neuropsychiatric diseases, allergic-respiratory diseases, and inflammatory bowel diseases, and a composition for prevention, treatment, and/or alleviation.

traducir

METHODS OF PREDICTING COMPLICATION AND SURGERY IN CROHN'S DISEASE

NºPublicación: US2019203295A1 04/07/2019

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

US_2012073585_A1

Resumen de: US2019203295A1

The present invention relates to prognosing, diagnosing and treating an aggressive form of Crohn's disease characterized by rapid progression to complication and/or surgery from the time of diagnosis. In one embodiment, the prognosis, diagnosis and treatment is based upon the presence of one or more genetic risk factors.

traducir

DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE BASED ON GENES

NºPublicación: US2019194754A1 27/06/2019

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

JP_2019516375_A

Resumen de: US2019194754A1

The present invention describes a method of prognosing high or low probability of developing an inflammatory bowel disease (IBD) in a subject and a method of diagnosing an inflammatory bowel disease (IBD) in a subject. The invention further provides for a method of identifying genes/genetic loci associated with a disease condition, such as IBD, CD and/or UC.

traducir

Method of diagnosing a dysbiosis

NºPublicación: AU2019203763A1 20/06/2019

Solicitante:

SMARTDNA PTY LTD

AU_2018253466_A1

Resumen de: AU2019203763A1

The present disclosure relates to methods of diagnosing a dysbiosis in a subject, methods of determining a suitable treatment, and methods of treating a dysbiosis. In some aspects, the present disclosure relates to diagnosing or determining a subtype of irritable bowel syndrome (IBS).

traducir

VARIANTS OF TNFSF15 AND DCR3 ASSOCIATED WITH CROHN'S DISEASE

NºPublicación: EP3498867A1 19/06/2019

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

JP_2018148931_A

Resumen de: EP3498867A1

Described herein are methods and compositions related to the discovery of associations in TNFSF15 15 and DcR3 genetic loci across in Caucasian, Puerto Rican, and Korean Crohn's Disease, as demonstrated via trans-ethnic fine mapping. The present invention provides methods of quantifying risk and diagnosing susceptibility to Crohn's disease in a subject by determining the presence of one or more risk variants are at the TNFSF15 (or TL1A) and/or DcR3 genetic loci.

traducir

METHOD OF TREATMENT OF GUT INFLAMMATORY DISEASES SUCH AS INFLAMMATORY BOWEL DISEASES (IBD) OR IRRITABLE BOWEL SYNDROME (IBS)

NºPublicación: US2019177433A1 13/06/2019

Solicitante:

INST NAT SANTE RECH MED [FR]
UNIV TOULOUSE 3 PAUL SABATIER [FR]
CENTRE NAT RECH SCIENT [FR]

WO_2017216352_A1

Resumen de: US2019177433A1

The invention is in the field of therapy of gut inflammatory diseases such as Inflammatory Bowel Diseases (IBD) or Irritable Bowel Syndrome (IBS) including Gluten hypersensitivity. The inventors showed that ELA2A secreted by epithelial cells in the extracellular space is over-expressed in IBD conditions degrading tight junction proteins and controlling cytokines expression. Overexpression of ELA2A conferred a pro-inflammatory phenotype both in cell expression systems and in vivo in animal model of IBD. The inventors also showed that ELA2 over-expressing intestinal epithelial cells increase the release of CXCL8 protein compared to control cells. The increased CXCL-8 protein release observed in cells overexpressing ELA2A is inhibited by ELAFIN addition to the culture, in a dose-dependent manner. In particular, the invention relates to inhibitors of Elastase ELA2A, for use in the treatment of Inflammatory Bowel Diseases, such as Crohn's Disease, Ulcerative Colitis, Celiac disease, and Pouchitis.

traducir

ANTIBODY TO CYTOLETHAL DISTENDING TOXIN OF CAMPYLOBACTER JEJUNI

NºPublicación: US2019178890A1 13/06/2019

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

US_2018231551_A1

Resumen de: US2019178890A1

The present invention describes methods for preventing IBS, reducing the likelihood of developing IBS and/or treating IBS by administering CDT inhibitors and/or CDT neutralizers to a subject in need thereof. The present invention also describes methods of eliciting a specific immune response and methods of vaccinating a subject to prevent IBS or to reduce the likelihood of developing or having IBS. The present invention further describes methods of diagnosing IBS by detecting the presence or absence of CDT or a CDT marker in a subject.

traducir

METHODS OF MANAGING HEPATIC STEATOSIS

NºPublicación: WO2019113280A1 13/06/2019

Solicitante:

UNIV EMORY [US]

Resumen de: WO2019113280A1

This disclosure relates to methods of using a specific binding agent that targets alpha4 beta7 integrin to treat or prevent fatty liver diseases such as, hepatic steatosis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). In certain embodiments, a specific binding agent that targets alpha4 beta7 integrin is an antibody. In certain embodiments, antibody that binds alpha4 beta7 integrin is vedolizumab. In certain embodiments, the subject is or is not diagnosed with inflammatory bowel disease.

traducir

SYSTEM FOR MONITORING STATE OF INFLAMMATORY BOWEL DISEASE

NºPublicación: WO2019103870A1 31/05/2019

Solicitante:

BOSTON SCIENT SCIMED INC [US]

US_2019150851_A1

Resumen de: WO2019103870A1

An example of a system for monitoring and treating a medical condition of a patient may include signal inputs to receive patient condition signals indicative of a state of inflammatory bowel disease (IBD), a signal processing circuit configured to process the patient condition signals and generate patient condition parameters indicative of the state of IBD using the processed patient condition signals, and a medical condition analyzer configured to analyze the patient condition parameters and determine the medical condition including the state of IBD using an outcome of the analysis. The patient condition parameters may include one or more physiological marker parameters each representative of a physiological marker of IBD and one or more quality of life parameters each being measure of quality of life of the patient.

traducir

NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES

NºPublicación: SG11201903737PA 30/05/2019

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

TW_201829461_A

Resumen de: SG11201903737PA

1 7 3 0 2 2 Log (AL I irdol 125 100 E 75 r„, 25 • 5C3D11 EC 50 = 1 nM 0 1 Lug obi oia 2 9E12E5 EC 50 =2.4 nM W O 20 18/08 107 4 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 03 May 2018 (03.05.2018) WIPO I PCT omit VIII °nolo III m H VIII IIIII 110 Immo oimIE (10) International Publication Number WO 2018/081074 Al (51) International Patent Classification: C07K 14/715 (2006.01) A61K 39/395 (2006.01) C07K 14/525 (2006.01) G01N 33/68 (2006.01) C07K 14/52 (2006.01) C12Q 1/68 (2018.01) CO7K 16/24 (2006.01) (21) International Application Number: PCT/US2017/058019 (22) International Filing Date: 24 October 2017 (24.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/413,188 26 October 2016 (26.10.2016) US (71) Applicant: CEDARS-SINAI MEDICAL CENTER [US/US]; 8700 Beverly Blvd., Los Angeles, California 90048 (US). (72) Inventors: BILSBOROUGH, Janine; 390 Pellburne Ct., Simi Valley, California 93065 (US). TARGAN, Stephan; 240 22nd St., Santa Monica, California 90402 (US). HEN- KLE, Bradley; #203, 1233 Nth Flores St., West Holly- wood, California 90069 (US). (74) Agent: BRESNAHAN, Matthew J.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, Cali- fornia 94304 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

traducir

METHOD AND APPARATUS FOR MONITORING STATE OF INFLAMMATORY BOWEL DISEASE

NºPublicación: US2019150851A1 23/05/2019

Solicitante:

BOSTON SCIENT SCIMED INC [US]

WO_2019103870_A1

Resumen de: US2019150851A1

An example of a system for monitoring and treating a medical condition of a patient may include signal inputs to receive patient condition signals indicative of a state of inflammatory bowel disease (IBD), a signal processing circuit configured to process the patient condition signals and generate patient condition parameters indicative of the state of IBD using the processed patient condition signals, and a medical condition analyzer configured to analyze the patient condition parameters and determine the medical condition including the state of IBD using an outcome of the analysis. The patient condition parameters may include one or more physiological marker parameters each representative of a physiological marker of IBD and one or more quality of life parameters each being measure of quality of life of the patient.

traducir

SYSTEM, COMPOSITION AND METHOD FOR THE DETECTION OF SPECTRAL BIOMARKERS OF A CONDITION AND PATTERNS FROM STOOL SAMPLES

NºPublicación: WO2019094341A1 16/05/2019

Solicitante:

CLINICAI INC [US]

Resumen de: WO2019094341A1

A system, composition and method detect diseases using a method for identifying spectral biomarkers and patterns from stool samples. In one embodiment, the system, composition and method may provide a non-invasive method for detecting colorectal cancer and precancerous polyps comprises subjecting stool samples from cancerous and non-cancerous subjects to hyperspectral spectroscopy and wherein differences in spectra indicates cancer, or assesses risk of development thereof. The system, composition and method may also include a method for identifying spectral biomarkers and patterns from stool samples from cancerous, precancerous and inflammatory bowel disease subjects.

traducir

SCREENING AND CULTURE METHOD

NºPublicación: US2019144911A1 16/05/2019

Solicitante:

OTAKARO PATHWAYS LTD [NZ]

AU_2016371363_A1

Resumen de: US2019144911A1

Methods of culturing and detecting a biomarker which may be associated with autoimmune diseases, in particular inflammatory bowel disease and Crohn's disease; also a screening method for substances suitable for the treatment of inflammatory bowel disease including Crohn's disease; the method including culturing a biomarker in a culture media which includes a culture broth, OADC, PANTA and Mycobactin J.

traducir

Discovering Population Structure From Patterns of Identity-By-Descent

NºPublicación: US2019147973A1 16/05/2019

Solicitante:

ANCESTRY COM DNA LLC [US]

MX_2017015224_A

Resumen de: US2019147973A1

Described are techniques for determining population structure from identity-by-descent (IBD) of individuals. The techniques may be used to predict that an individual belongs to zero, one or more of a number of communities identified within an IBD network. Additional data may be used to annotate the communities with birth location, surname, and ethnicity information. In turn, these data may be used to provide to an individual a prediction of membership to zero, one or more communities, accompanied by a summary of the information annotated to those communities.

traducir

METHOD FOR JUDGING ONSET POSSIBILITY OF LARGE BOWEL CANCER

NºPublicación: EP3483282A1 15/05/2019

Solicitante:

HANUMAT CO LTD [JP]
EA PHARMA CO LTD [JP]

KR_20190045146_A

Resumen de: EP3483282A1

The present invention provides a method for determining the likelihood of colorectal cancer development in a human ulcerative colitis patient, the method including: a measurement step of measuring methylation rates of one or more CpG sites present in specific differentially methylated regions in DNA recovered from a biological sample collected from the human ulcerative colitis patient; and a determination step of determining the likelihood of colorectal cancer development in the human ulcerative colitis patient based on average methylation rates of the differentially methylated regions which are calculated based on the methylation rates measured in the measurement step and a preset reference value or a preset multivariate discrimination expression, in which the reference value is a value for identifying a cancerous ulcerative colitis patient and a non-cancerous ulcerative colitis patient, which is set for the methylation rate of each differentially methylated region, and the multivariate discrimination expression includes, as variables, average methylation rates of one or more differentially methylated regions among the specific differentially methylated regions.

traducir

BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE

NºPublicación: EP3481964A1 15/05/2019

Solicitante:

CAMBRIDGE ENTPR LTD [GB]

CN_109477145_A

Resumen de: WO2018007872A1

The present invention provides a method of assessing whether an individual is at high risk or low risk of inflammatory bowel disease (IBD) progression by determining the expression level of two or more genes in a whole blood sample. Also provided are methods for treating IBD in an individual who is determined to be at high risk or low risk for IBD progression, and kits for assessing whether an individual is at high risk or low risk for IBD progression. Arrays, and methods of providing arrays, of patient-identified selected gene expression products from a whole blood sample of a patient are also provided.

traducir

DIAGNOSIS OF CONSTIPATION BY ANALYSIS OF METHANE CONCENTRATION

NºPublicación: US2019136286A1 09/05/2019

Solicitante:

CEDARS SINAI MEDICAL CENTER [US]

US_2008182291_PA

Resumen de: US2019136286A1

Disclosed are methods of diagnosing constipation and constipation-predominant irritable bowel syndrome by screening for the presence of abnormally high levels of methane and/or methanogenic organisms in a subject.

traducir

METHODS FOR PREDICTING ACUTE SEVERE COLITIS TREATMENT RESPONSE

NºPublicación: US2019136324A1 09/05/2019

Solicitante:

INSERM INSTITUTE NATIONAL DE LA SANTE ET DE LA RES MEDICALE [FR]
UNIV PARIS DIDEROT PARIS 7 [FR]
ASSIST PUBLIQUE HOPITAUX DE PARIS APHP [FR]
UNIV BORDEAUX [FR]
CHU DE BORDEAUX [FR]
UNIV PARIS XIII PARIS NORD [FR]

Resumen de: US2019136324A1

The present invention relates to methods for predicting acute severe colitis treatment response. Currently, there is no biomarker of drug response. The present invention provides the first prediction tool for responses to first- and second-line treatments in acute severe ulcerative colitis. Putative mRNA targets of dysregulated microRNAs were identified from patient biopsies. One classifier of fifteen colonic microRNAs plus five biological values at admission were identified with a prediction accuracy of 96.6% for discriminating responders from non-responders to steroids. Using a similar method, 6 and 4 mucosal microRNA-based algorithms were identified to classify responders from non-responders to infliximab and cyclosporine. In particular, the present invention relates to methods for predicting acute severe colitis treatment response by measuring the expression levels of several miRNAs selected from the group consisting of hp_hsa-mir-3934, hp_hsa-mir-100, hsa-miR-718, hp_hsa-mir-193b, hsa-miR-3150a-5p, hp_hsa-mir-1260b, hsa-miR-938, hsa-miR-518b and hsa-miR-1468.

traducir

Therapy of multiple organ system failure by anti-toxin antibodies and prophylaxis by anaerobic toxoids

NºPublicación: US2019127450A1 02/05/2019

Solicitante:

KHAFAGY MEDHAT [EG]
KHAFAGY AYATALLAH [US]

Resumen de: US2019127450A1

Multiple organ system failure constitutes the most common cause of mortality in intensive care units all over the world. About more than 70 thousand deaths from multiple organ system failure occur every year in the US only. It has been postulated with no definite proof that it is due to translocation of endotoxin from the lumen of the small bowel. Antibodies against anaerobic organisms (mainly clostridia) were found in high concentration in 7 of 8 patients diagnosed with multiple organ system failure from intensive care units in Cairo, Egypt. We suggest that these patients could be saved by antibodies against these toxins prepared in horses injected with anaerobic toxoids, similar to saving patients with toxicity from botulism caused by clostridium botulinum. Prophylaxis against anaerobic sepsis could be achieved by anaerobic toxoids in rats and cohort of 445 patients that underwent major surgery in Cairo, Egypt.

traducir

A companion diagnostic method for use in the treatment of irritable bowel syndrome with dietary interventions or faecal microbiota transplant

NºPublicación: AU2017342088A1 02/05/2019

Solicitante:

GENETIC ANALYSIS AS

CA_3039144_A1

Resumen de: AU2017342088A1

The present invention provides a diagnostic method which may be used to determine the likelihood that a subject with Irritable Bowel Syndrome (IBS) will respond to treatment with an IBS intervention diet or faecal microbiota transplant (FMT). In particular, the method may be used to predict, or determine the likelihood of, a positive response of the subject with IBS to treatment with an IBS intervention diet or FMT, especially to determine the likelihood that the dietary intervention or FMT may have a positive (i.e. beneficial) effect on the subject's Gl tract, specifically the Gl tract microbiota, or other symptoms or complications of IBS (e.g. reducing severity thereof). The method of the present invention is based on analysing the abundance of certain bacteria in Gl tract samples, e.g. by nucleic acid analysis.

traducir

Bacteria inducing Th1 cells

NºPublicación: AU2017354716A1 02/05/2019

Solicitante:

UNIV KEIO

CA_3041277_A1

Resumen de: AU2017354716A1

It was discovered that saliva derived from patients with Crohn's disease or ulcerative colitis markedly increases Th1 cells in the colon when administered orally to sterile mice. Furthermore, bacteria that trigger induction of strong Th1 cells in the colon when established in the intestinal tract were successfully isolated from the intestinal flora of mice in which this increase in Th1 cells was observed.

traducir

DIAGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES

NºPublicación: US2019120862A1 25/04/2019

Solicitante:

DYAX CORP [US]

JP_2017500584_A

Resumen de: US2019120862A1

Methods, kits and compositions for diagnosing and treating autoimmue diseases such as rheumatiodi arthritis, Crohn's disease, and ulcerative colitis.

traducir

METHOD OF TREATMENT OF GUT INFLAMMATORY DISEASES SUCH AS INFLAMMATORY BOWEL DISEASES (IBD) OR IRRITABLE BOWEL SYNDROME (IBS)

NºPublicación: EP3471757A1 24/04/2019

Solicitante:

INST NAT SANTE RECH MED [FR]
UNIV TOULOUSE 3 PAUL SABATIER [FR]
CENTRE NAT RECH SCIENT [FR]

US_2019177433_A1

Resumen de: WO2017216352A1

The invention is in the field of therapy of gut inflammatory diseases such as Inflammatory Bowel Diseases (IBD) or Irritable Bowel Syndrome (IBS) including Gluten hypersensitivity. The inventors showed that ELA2A secreted by epithelial cells in the extracellular space is over-expressed in IBD conditions degrading tight junction proteins and controlling cytokines expression. Overexpression of ELA2A conferred a pro-inflammatory phenotype both in cell expression systems and in vivo in animal model of IBD. The inventors also showed that ELA2 over-expressing intestinal epithelial cells increase the release of CXCL8 protein compared to control cells. The increased CXCL-8 protein release observed in cells overexpressing ELA2A is inhibited by ELAFIN addition to the culture, in a dose-dependent manner. In particular, the invention relates to inhibitors of Elastase ELA2A, for use in the treatment of Inflammatory Bowel Diseases, such as Crohn's Disease, Ulcerative Colitis, Celiac disease, and Pouchitis.

traducir

METHODS FOR MONITORING VEDOLIZUMAB TREATMENT

Nº publicación: WO2019073391A1 18/04/2019

Solicitante:

NESTEC SA [CH]

Resumen de: WO2019073391A1

The disclosure provides a method for predicting that a subject having inflammatory bowel disease (IBD) will have a clinical response or remission to an anti-α4β7 integrin during the course of therapy by assessing the concentration of the anti-α4β7 integrin drug at the induction or maintenance phase, respectively in a sample from the subject. The disclosure also provides a method for predicting whether a subject having inflammatory bowel disease (IBD) will be a remitter to an anti-α4β7 integrin drug treatment regimen by detecting the presence or level of at least one predictive marker.

traducir

Página1 de 2 nextPage por página

punteroimgVolver